xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.
The ATR inhibitor BAY 1895344 appeared promising in patients with a range of advanced, heavily pre-treated cancers in a dose-escalation portion of a phase 1 clinical trial.
The FDA issued the final guidance in order to help improve the information available to patients and health care providers about the risks of breast implants.
TLX591-CDx (illumet) is a radiopharmaceutical targeting prostate-specific membrane antigen intended for the imaging of prostate cancer using positron emission tomography.
These study findings suggested that topical minoxidil and procedural interventions may aid in the treatment of persistent radiation-induced alopecia among patients with primary central nervous system tumors or head and neck sarcomas.
This study found that among clinical trials in which patients with non-small cell lung cancer were treated with atezolizumab, multiorgan immune-related adverse events were reported in 5.4%.